Agendia Employee Directory
Biotechnology ResearchCalifornia, United States201-500 Employees
Agendia is an Irvine, California-based biotechnology company focused on precision oncology for early-stage breast cancer. It offers MammaPrint, a 70-gene recurrence assay, and BluePrint, an 80-gene molecular subtyping test; MP is FDA-cleared for risk of recurrence and CE-marked, while BP is CE-marked but not FDA-cleared, and both can be ordered on core biopsies or surgical specimens. The tests are supported by clinical, guideline, peer-reviewed, and real-world evidence, and analyses are conducted in a CLIA-certified laboratory. In 2026, NCCN updated its guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early-stage breast cancer. The company operates within the biotechnology research space, aligning its genomic testing with guideline-driven, precision medicine approaches for breast cancer.